# R1 Clinical-Safety Review: dysgerminoma.md

VERDICT: APPROVE

## 1. SAFETY — pass
No unsafe, misleading, or harmful directive. Key claims are correct standard-of-care and
appropriately hedged:
- Stage IA fertility-sparing surgery with observation (no routine adjuvant chemo) is the correct
  and specific germ-cell exception — not overstated.
- Fertility-sparing surgery even with metastatic disease is legitimate for chemosensitive GCTs.
- AFP normal in pure dysgerminoma; a rising AFP flags a mixed GCT component and prompts
  re-evaluation — clinically important and correctly framed as a red flag, not a false reassurance.
- Contralateral ovary / gonadal dysgenesis / Y-karyotype -> gonadoblastoma risk is handled with
  a referral pathway, not a definitive directive. No absolute "always/never" that could cause harm.
- Radiotherapy correctly demoted to a narrow chemoresistant/non-fertility role.

## 2. GROUNDING — pass
Treatment approach is consistent with DeVita/NCCN standard of care. Adjuvant platinum-based
bleomycin-etoposide-cisplatin is correctly presented as extrapolated from testicular GCT experience.
No fabricated or outdated regimen. Critically, the draft explicitly declines to invent a second-line
regimen, cycle count, or surveillance schedule ("What DeVita is silent on"), which is the correct
decision-support posture.

## 3. DOSE-FREE — pass
Grep for mg / mg-m2 / AUC / cycle-numbers / q-intervals returned zero hits. "FIGO stage IA" is
staging, not dosing. Clean.

## 4. SCOPE — pass
Framed as decision-support: repeated routing to gyn-onc MDT / specialist germ-cell tumour board,
fertility-preservation referral before treatment, and referral-back on relapse/atypical markers.
No directive dosing or definitive single-path mandate.

## 5. ADVERSARIAL FLAGS — resolved
The .verdict.md's three previously-held cross-organ-contamination issues are all present-and-fixed
in the current sidecar, each correctly relabelled "(general oncology standard, not from DeVita's
section on this disease)":
- beta-hCG / syncytiotrophoblast-like giant cells — labelled (line 55-56).
- gonadoblastoma / Y-karyotype / bilateral gonadectomy — labelled in both the treatment bullet
  (line 24-25) and the referral bullet (line 72-73).
- Alkaline phosphatase alongside LDH — verified by adversary as verbatim-DeVita, correctly left
  unlabelled (line 53).
No DeVita mis-attribution remains on any therapeutic/regimen claim.

## Advisory (non-blocking)
- Opening ranking "the most common malignant ovarian germ-cell tumour" (line 3-4) is epidemiologically
  correct and clinically uncontroversial, but per the adversary is DeVita-unstated. It sits under a
  blanket "Sources: DeVita" citation. Not a regimen/drug/safety claim, so not a blocker; recommend a
  future "(general oncology standard)" tag for citation hygiene, consistent with how the three
  labelled items were handled.
- "High-volume gyn-onc surgeon / guideline-adherence" outcome sentence (line 68-69) is grounded in
  the surrounding DeVita ovarian chapter (SEER/Bristow), not the germ-cell passage — acceptable,
  same-chapter, not cross-organ.

goldens changed: no (intended: n/a — reference-content narrative, no engine/golden output)
